Novimmune

Light Chain Bioscience Chooses Genedata to Digitalize Cell Line & Bioprocess Development

Retrieved on: 
Tuesday, June 27, 2023
Immortalised cell line, CSO, CLD, DSP, CMC, Research, USP, RNA, Antibody, Light, R2D, Architecture, Fine chemical, Novimmune

BASEL, Switzerland, June 27, 2023 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Light Chain Bioscience, a brand of Novimmune, has chosen the Genedata Bioprocess® enterprise platform to streamline and automate cell line and early bioprocess development of their lead candidates.

Key Points: 
  • BASEL, Switzerland, June 27, 2023 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Light Chain Bioscience, a brand of Novimmune, has chosen the Genedata Bioprocess ® enterprise platform to streamline and automate cell line and early bioprocess development of their lead candidates.
  • Genedata Bioprocess is fully integrated with Genedata Biologics and supports the entire end-to-end development process at Light Chain Bioscience across CLD, USP, DSP, and analytics operations.
  • The platform integrates all data generated along the biotherapeutics development and CMC process, including cell line development, upstream, downstream, and analytics functions.
  • "We are delighted to see Light Chain Bioscience expanding their usage of the Genedata Biopharma Platform to now integrate both their discovery and development operations," said Othmar Pfannes, Ph.D., CEO of Genedata.

Vivtex Announces Promotion of Maureen Deehan To Chief Executive Officer

Retrieved on: 
Tuesday, February 21, 2023
Compugen (company), Science, Biotechnology, Faculty, Genentech, Drug development, Doctor of Philosophy, University of Toronto Faculty of Medicine, University of Glasgow, Novimmune, Pharmaceutical industry, Medicine

CAMBRIDGE, Mass., Feb. 21, 2023 /PRNewswire/ -- Vivtex Corporation, a pre-clinical drug development company with a high throughput GI screening technology, that converts drugs requiring needle injection into oral formulations, announced today that Maureen Deehan, Ph.D., has been promoted to Chief Executive Officer.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 21, 2023 /PRNewswire/ -- Vivtex Corporation, a pre-clinical drug development company with a high throughput GI screening technology, that converts drugs requiring needle injection into oral formulations, announced today that Maureen Deehan, Ph.D., has been promoted to Chief Executive Officer.
  • Dr. Deehan succeeds former CEO, James Winschel, who joined the company in 2018 as the Chief Financial Officer.
  • Dr. Deehan joined Vivtex in December 2022 as the Chief Business & Operating Officer.
  • We have a state-of-the-art, AI-based, intact GI screening technology and excellent pre-clinical data for our programs, both in-house and with our established biotech & pharma partners," said Maureen Deehan, Ph.D., CEO of Vivtex.

Light Chain Bioscience Adopts Genedata Biologics for Next-Gen Antibody Engineering

Retrieved on: 
Tuesday, April 19, 2022
CEO, Decision-making, Bispecific monoclonal antibody, Monoclonal antibody, Software, Patient, ROI, Efficiency, Light, CSO, Immunoglobulin G, CD47, Intelligence, Antibody, Risk, Software as a service, D, Fine chemical, Vaccine, Novimmune, Genedata

BASEL, Switzerland, April 19, 2022 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Light Chain Bioscience, a brand of Novimmune, has chosen the Genedata Biologics® workflow platform to accelerate discovery and development of proprietary multi-specific antibodies. Headquartered in the Swiss biotech hub around Lake Geneva, Light Chain Bioscience is focused on generating truly human bispecific antibodies for immuno-oncology and other therapeutic indications.

Key Points: 
  • Genedata Biologics will act as our organizational memory to structure and protect our assets and ensure that data can always be accessed and found," said Nicolas Fischer, Ph.D., CEO at Light Chain Bioscience.
  • Genedata Biologics is also being used for proprietary antibody technology, both for Light Chain Bioscience's internal programs and for their partners.
  • "We are pleased that Light Chain Bioscience, a cutting-edge and proven biotech, has chosen Genedata Biologics to digitalize their biopharma discovery operations," said Othmar Pfannes, Ph.D., CEO of Genedata.
  • Light Chain Bioscience is a clinical-stage company focused on the discovery and development of therapies based on bispecific and multi-specific antibody formats.

DGAP-News: Topas Therapeutics Appoints Cristina de Min, M.D. as Chief Medical Officer

Retrieved on: 
Tuesday, February 15, 2022
Roche, Patient, Allergy, IL-6, Novimmune, Company, TPM, Life cycle, Rheumatology, Rheumatoid arthritis, Type 1 diabetes, Therapy, Degenerative disease, Medical director, Drug development, Pharmaceutical industry, Topas, Pemphigus vulgaris

Topas Therapeutics Appoints Cristina de Min, M.D.

Key Points: 
  • Topas Therapeutics Appoints Cristina de Min, M.D.
  • as Chief Medical Officer
    She will drive the advancement of Topas' development programs, including lead clinical program TPM203 for treatment of pemphigus vulgaris and TPM502 for treatment of celiac disease
    Topas Therapeutics GmbH (Topas), a private biotechnology company developing immune tolerance-inducing drugs to treat and potentially cure a variety of autoimmune diseases, today announced the appointment of Cristina de Min, M.D., as Chief Medical Officer.
  • Klaus Martin, Ph.D., Chief Executive Officer, said: "I am thrilled to welcome Cristina to Topas.
  • Cristina de Min, M.D., Chief Medical Officer, said: "I am excited to join the Topas team.

Global Rybrevant Bispecific Antibody Market to 2028 - Featuring Affimed Therapeutics, Amgen and Eli Lilly Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, November 5, 2021
Pharmaceutical, Health, Oncology, Efficiency, Sanofi, Lung cancer, MET, Stomach cancer, US FDA, Roche, ACC, Growth, Research, Adenoid cystic carcinoma, Janssen Pharmaceuticals, Epitope, Cancer, Esophageal cancer, Clinical trial, Carboplatin, Large-cell lung carcinoma, Therapy, Data, NSCLC, EGF, Monoclonal antibody, Time, Survival, Patent, Novimmune, Patient, AstraZeneca, Adult, Vaccine, Fine chemical

It is analyzed that the market will witness high compound annual growth rates to surpass US$ 4 Billion by 2028.

Key Points: 
  • It is analyzed that the market will witness high compound annual growth rates to surpass US$ 4 Billion by 2028.
  • Apart from this, the favorable reimbursement policies including Janssen Care Path will also boost the uptake of drug in the market.
  • Furthermore, the subsequent years will see approval of Rybrevant in different regions, which will further boost the growth of market.
  • The major key players in the market are Amgen, Genmab, Eli Lilly, NovImmune, Sanofi, Roche, AstraZeneca, and several others.

Global Crohn's Disease Clinical Trial Pipeline Research Report 2021: Phase 3, Phase 2, Phase 1, Preclinical Research, and Discovery Stage - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021
Pharmaceutical, Health, Clinical trials, Medical specialties, Health sciences, Health, Drug discovery, Autoimmune diseases, Clinical research, Pharmaceutical industry, Abdominal pain, Crohn's disease, Clinical trial, Novimmune, Management of Crohn's disease

The "Global Crohn's Disease Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Crohn's Disease Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Crohn's Disease Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Crohn's Disease market.
  • It covers emerging therapies for Crohn's Disease in active clinical development stages including early and late stage clinical trials.
  • The report provides Crohn's Disease pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Global Bispecific Antibody Market to 2028 - Opportunity, Drug Sales, Price & Clinical Trials Insights - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 23, 2021
Oncology, Health, Other Science, Clinical trials, Science, Pharmaceutical, Biotechnology, Medical specialties, Clinical medicine, Medicine, Immunology, Monoclonal antibodies, Biotechnology, Bispecific monoclonal antibody, Antibody, Emicizumab, Istiratumab, Novimmune

The "Global Bispecific Antibody Market Opportunity, Drug Sales, Price & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Bispecific Antibody Market Opportunity, Drug Sales, Price & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.
  • To conclude, it can be stated that the overall therapy market achievements are commitment to cause a total advancement in the global cancer therapeutics market by acting broad spectrally.
  • Global Bispecific Antibody Market Opportunity, Drug Sales, Price & Clinical Trials Insight 2028 Report Highlights:
    Global Bispecific Antibody Market Opportunity: > US$ 18 Billion
    Global Bispecific Antibody Market Growth Rate: 121% CAGR (2016-2020)
    Global Bispecific Antibody Sales In 2020: >55%
    Bispecific Antibodies In Clinical Trials: More Than 400 Antibodies
    The unique achievements gathered through monoclonal antibody market led to the identification of novel wave of antibody market classified as Bispecific cancer antibody market.
  • Currently 2 Bispecific Antibodies Blincyto And Hemlibra Are Commercially Available In Market, Hemlibra Accounts For More Than 85% Of Global Bispecific Antibody Market
    In the past few years, global bispecific cancer antibody market has cleared its clinical evaluation for different types of cancers which involves: cancer at early stage, last stage and solid cancers.

Sorrento Receives FDA Clearance to Start Clinical Trial of Anti-CD47 Antibody, Discovered from Fully Human G-MAB Library, for Treatment of Multiple Malignancies

Retrieved on: 
Tuesday, March 2, 2021
CD47, Cancer research, Monoclonal antibodies, Medicine, Clinical medicine, Medical specialties, Novimmune, Antibody-drug conjugates

The initial clinical trial will be a basket trial entitled A Phase 1B, Open-Label, Dose-Escalation Study of the Safety and Efficacy of STI-6643, an Anti-CD47 Human Monoclonal Antibody, in Patients with Selected Relapsed or Refractory Malignancies.

Key Points: 
  • The initial clinical trial will be a basket trial entitled A Phase 1B, Open-Label, Dose-Escalation Study of the Safety and Efficacy of STI-6643, an Anti-CD47 Human Monoclonal Antibody, in Patients with Selected Relapsed or Refractory Malignancies.
  • Various solid and hematologic cancers exploit CD47 expression to evade immunological eradication, and its overexpression is clinically correlated with poor prognoses.
  • STI-6643 has the potential to be a best-in-class product if these preclinical benefits are able to be reproduced in human trials.
  • RTX has completed a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients.

Global BiTE Antibodies Market (2021 to 2025) - Price, Sales & Clinical Trials Insights - ResearchAndMarkets.com

Retrieved on: 
Monday, February 22, 2021
Biotechnology, Health, Oncology, Medical specialties, Immunology, Clinical medicine, Medicine, Monoclonal antibodies, Antibody, Glycoproteins, Cancer, Antineoplastic drugs, Istiratumab, Novimmune

Also, the association of the entire market with strong and robust clinical pipeline and research activities in the past as well as in present is believed to completely revolutionize the entire market opportunities held within bispecific cancer antibody market.

Key Points: 
  • Also, the association of the entire market with strong and robust clinical pipeline and research activities in the past as well as in present is believed to completely revolutionize the entire market opportunities held within bispecific cancer antibody market.
  • The large penetration of the bispecific cancer antibody drugs against different cancer indications is also leading to cause certain changes in the entire cancer market.
  • As per the report findings, it is observed that the entire market is linked with hundreds of high-performance drugs which have led to a decline in the global cancer mortality rate.
  • It is analyzed that the future terms of the market will make the market recognized as a standard and dominating treatment regimen for millions of patients.

Arch Oncology to Participate in Upcoming Conferences

Retrieved on: 
Tuesday, February 16, 2021
Medical specialties, Medicine, Health care, Cancer immunotherapy, CD47, Multiple myeloma, Immunology, Novimmune, Molecular Partners

BRISBANE, Calif. and ST. LOUIS, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the companys participation at upcoming healthcare investor conferences:

Key Points: 
  • BRISBANE, Calif. and ST. LOUIS, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the companys participation at upcoming healthcare investor conferences:
    Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class antibody therapies for the treatment of patients with solid tumors and hematologic malignancies.
  • The Companys next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class.
  • Arch Oncologys lead product candidate AO-176 is in Phase 1/2 clinical trials for the treatment of patients with select solid tumors and with multiple myeloma, both as monotherapy and in combination with standard therapies.
  • In addition, the Company is advancing a pipeline of antibody programs for the treatment of cancer.